As real-world evidence assumes a growing role in oncology research, regulatory evaluation, and clinical decision-making, the quality of underlying data has...
Strategic partnership integrates Pluristyx's clinical-grade iPSC platform into Made Scientific's CDMO services, giving developers a single-source path fr...
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agon...
As oncology practices face increasing patient demand and looming workforce shortages, advanced practice providers (APPs) are becoming an essential part of ...
As oncology care becomes increasingly personalized and technology-enabled, digital tools are playing a growing role in improving patient outcomes beyond th...
SGS, the world's leading testing, inspection and certification company, is pleased to announce that it has acquired CMIC, INC., a specialized provider of...
ADC Therapeutics SA announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in co...
MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced that it has secured the FDA's agreement to conduct a si...
Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech company dedicated to improving outcomes for patients with coronary and peripheral artery dis...
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease The US Food and Drug Administration (FDA) has granted p...
Mevion Medical Systems has signed a definitive purchase agreement to bring the MEVION S250-FIT Proton Therapy System™ to Tam Anh General Hospital i...
Award funds collaboration with leading Parkinson’s researcher, Dr. Tim Greenamyre, to investigate a novel therapeutic approach for Parkinson&rsqu...
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy® 7.2 mg in a...
United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineerin...
© 2026 Biopharma Boardroom. All Rights Reserved.
